News | October 31, 2013

New Data Continues to Show Significant, Sustained Blood Pressure Reduction With Vessix Renal Denervation System

REDUCE-HTN data presented at TCT demonstrates excellent safety profile

renal denervation clinical trial study hypertension vessix boston scientific
October 31, 2013 — Patients treated with the Boston Scientific Vessix Renal Denervation System experienced a significant and sustained reduction in blood pressure, according to new data presented today at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2013) in San Francisco. An interim analysis of 139 patients enrolled in the REDUCE-HTN post market study affirms the device safety profile and effective treatment for resistant hypertension.
 
"In the REDUCE-HTN study, 85 percent of patients treated with the Vessix system experienced a clinically-meaningful decrease in blood pressure," said Horst Sievert, M.D., Ph.D., director, Cardiovascular Center Frankfurt, Sankt Katharinen Hospital, Frankfurt, Germany and principal investigator, REDUCE-HTN clinical program.  "In my opinion, the large patient cohort and rigorous analysis of the study suggest that renal denervation using bipolar technology will be an important part of the treatment algorithm for a wide variety of patients with resistant hypertension."
 
Renal denervation with the Vessix system is a minimally invasive procedure in which a balloon catheter is fed through the arterial vascular system and positioned in the renal arteries, the major blood vessels that lead to the kidneys. The physician then delivers low-power radiofrequency (RF) energy to disrupt the nerves surrounding the renal arteries in which hyperactivity contributes to uncontrolled high blood pressure. The Vessix system is the only renal denervation system to utilize bipolar energy to disrupt these nerves, providing a more localized and precise approach.
 
The REDUCE-HTN post market study enrolled 146 patients at 23 centers in Europe, Australia and New Zealand and is evaluating the ability of the Vessix System to reduce blood pressure at six months compared to the pre-treatment baseline blood pressure. Patients enrolled in the program are required to have a systolic blood pressure of at least 160 mmHg despite taking three or more antihypertensive medications.
 
Interim data highlights of the study include:
  • A significant 24.6 mmHg reduction in systolic blood pressure (p < 0.0001) at six months;
  • A sustained 29.6 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available;
  • A clinically meaningful decrease in office systolic blood pressure at both six and 12 months in 85 percent of patients in the trial;
  • Success reducing blood pressure in a variety of subgroups, including both men and women, patients with type 2 diabetes and patients age of 65 or older;
  • A strong safety profile with no occurrence of prespecified acute safety events and eight procedure-related serious adverse events (5.5 percent) among the 146 patients; and
  • A wide range of anatomies that were treated, including accessory renal arteries.
The Vessix system is a highly differentiated and advanced renal denervation system that features an intuitive push-button interface, a short 30-second treatment time and an over-the-wire, balloon-based approach familiar to most cardiac and vascular specialists.  The Vessix System has both CE mark and Therapeutic Goods Administration (TGA) approval and is currently available for sale in Europe, the Middle East, Australia, New Zealand and select markets in Asia.  The Vessix system is an investigational device and not available for sale in the United States.
 
For more information: www.bostonscientific.com, www.ccapr.com
 

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init